Verastem (VSTM) Stock Research

Today

Verastem price target lowered by $1 at Mizuho, here's why

VSTM

12:58 PM

Friday

Verastem price target lowered by $2 at Guggenheim, here's why

VSTM

Aug 7, 7:33 AM

Thursday

Verastem reports Q2 adjusted EPS (31c), consensus (44c)

VSTM

Aug 6, 4:02 PM

Over a week ago

Verastem doses first patients in Target-D 203 Phase 2 trial

VSTM

Jul 28, 4:04 PM

Verastem doses first patient in TARGET-D 202 Phase 2 trial

VSTM

Jul 22, 4:01 PM

Citizens healthcare analysts hold an analyst/industry conference call

Jul 7, 3:53 PM

Verastem price target lowered by $1 at RBC Capital, here's why

VSTM

Jul 7, 7:31 AM

Verastem reports 'positive' preliminary data from ongoing TARGET-D trial

VSTM

Jun 23, 4:02 PM

Verastem price target lowered by $7 at Jefferies, here's why

VSTM

Jun 23, 8:34 AM

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

VSTM

Jun 17, 7:33 AM

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

VSTM

Jun 16, 4:02 PM

Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375

VSTM

Jun 3, 4:21 PM

Verastem announces FDA Fast Track designation for VS-7375

VSTM

Jun 3, 4:02 PM

Verastem appoints Michael Bailey to board of directors

VSTM

May 26, 7:37 AM

Verastem price target lowered by $2 at Mizuho, here's why

VSTM

May 14, 7:22 AM

Verastem price target lowered by $1 at BTIG, here's why

VSTM

May 8, 7:26 AM

Verastem price target raised by $2 at Alliance Global, here's why

VSTM

May 8, 7:04 AM

Verastem reports Q1 adjusted EPS (43c), consensus (47c)

VSTM

May 7, 4:03 PM

Verastem announces launch of Reimagine Recurrent LGSOC campaign

VSTM

Apr 30, 7:47 AM

Verastem announces two-year median follow-up data on AVMAPKI FAKZYNJA combo

VSTM

Apr 10, 7:04 AM

Verastem assumed with a Buy at Jefferies

VSTM

Mar 30, 8:55 AM

Verastem management to meet with Cantor

VSTM

Mar 26, 5:02 PM